News & Events

Date Title  
11/14/19
SAN DIEGO , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss, announces that Bill Plovanic
11/08/19
SAN DIEGO , Nov. 08, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the third quarter
11/05/19
Real-world results from 222 consecutive patients treated with the Obalon Balloon System demonstrate clinically meaningful weight loss with no serious adverse events SAN DIEGO , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a weight loss solutions company with the
10/31/19
SAN DIEGO , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to release its third quarter 2019
10/24/19
Solidified leadership and strengthened financial position in place to leverage the Company’s safe and effective weight loss system in the retail medicine setting SAN DIEGO , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a San Diego-based weight loss solutions company
10/22/19
SAN DIEGO , Oct. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for non-surgical weight loss, announces it has treated the first patients at its Company-owned
10/03/19
SAN DIEGO , Oct. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a San Diego-based company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss, announces that it has retired the
09/03/19
Leading bariatric surgeon and authority in the field to oversee medical activities for the Obalon Center for Weight Loss located in San Diego, CA. SAN DIEGO , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a San Diego -based company focused on commercializing the
08/06/19
SAN DIEGO , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (Nasdaq: OBLN) (the “Company”) , a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced the
08/05/19
SAN DIEGO , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that William Plovanic ,
08/02/19
SAN DIEGO , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics Inc. (Nasdaq: OBLN) (the “Company”) , a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced the
07/24/19
OBLN common stock expected to begin trading on a split-adjusted basis on July 25, 2019 SAN DIEGO , July 24, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled
07/24/19
SAN DIEGO , July 24, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for
07/23/19
Retail site to focus exclusively on treating qualified individuals with the Obalon Balloon System SAN DIEGO , July 23, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled
07/22/19
SAN DIEGO , July 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to release its
07/16/19
Expands the Company’s intellectual property estate to 22 issued U.S. patents SAN DIEGO , July 16, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon
07/10/19
Recent equity capital raising activities position the company to pursue commercial strategy intended to more efficiently leverage the Obalon Balloon System SAN DIEGO , July 10, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company
06/24/19
New clinical data highlight convenience, efficiency, and safety of Obalon’s proprietary Navigation and Touch Dispenser systems to achieve reliable balloon administration without the use of x-ray SAN DIEGO , June 24, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc.
06/10/19
Experienced executive with successful track record of leading strategic growth initiatives, including national chain of retail cosmetic surgery clinics SAN DIEGO , June 10, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the
06/04/19
Expands the Company’s intellectual property estate to 20 issued US patents SAN DIEGO , June 04, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon
05/23/19
SAN DIEGO , May 23, 2019 (GLOBE NEWSWIRE) -- OBALON THERAPEUTICS, INC. (NASDAQ: OBLN) (“Obalon” or the “Company”) , a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today
05/21/19
Results from over 1,400 patients treated across 143 sites with Obalon’s non-surgical weight loss solution continue to affirm the safety and effectiveness of the Obalon Balloon System SAN DIEGO , May 21, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc.
05/17/19
SAN DIEGO , May 17, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it received two written
04/11/19
SAN DIEGO , April 11, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that the Company has retained
04/03/19
SAN DIEGO , April 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced an organizational
03/14/19
SAN DIEGO , March 14, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Kelly Huang ,
02/27/19
SAN DIEGO , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ) announces the first commercial use of the Obalon Navigation System™ and Touch™ Inflation Dispenser for balloon administration. The Obalon Navigation System and Touch Inflation Dispenser are intended to improve
02/22/19
Obalon Navigation System™ with Touch™ Inflation Dispenser are intended to increase adoption of the Obalon Balloon by improving ease of administration and eliminating the need for x-ray imaging on placement SAN DIEGO , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc.
02/22/19
SAN DIEGO , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its audited financial
02/15/19
SAN DIEGO , Feb. 15, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that it plans to release
01/03/19
SAN DIEGO , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, promotes Amy VandenBerg to Chief
01/02/19
SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it plans to host a
01/02/19
SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA -approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today completed the succession plan
IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click onSafety Information and Patient Labeling